Is an anticholinergic agent superior to a β2-agonist in improving dyspnea and exercise limitation in COPD?

Chest

Volumn 108, Issue 3, 1995, Pages 730-735

  Blosser, S A ^a   Maxwell, S L ^a   Reeves Hoche, M K ^a   Localio, A R ^a   Zwillich, C W ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

bronchodilators; COPD; dyspnea; exercise tolerance

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; IPRATROPIUM BROMIDE; SALBUTAMOL;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG POTENCY; DYSPNEA; EXPIRATORY FLOW RATE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029147385     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.108.3.730     Document Type: Article

References (20)

1. Braun SR McKenzie WN Copeland C A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med 149 1989 544 547
2. Braun SR. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med 91 suppl A 1991 28s 32s
3. Chan CS Brown IG Kelly CA Bronchodilator responses to nebulised ipratropium and salbutamol singly and in combination in chronic bronchitis. Br J Clin Pharmacol 17 1984 103 105
4. Gross NJ. Anticholinergic agents in chronic bronchitis and emphysema. Postgrad Med J 63 suppl l 1987 29 34
5. Tashkin DP Ashutosh K Bleeker ER Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. Am J Med 81 suppl 5A 1986 81 90
6. Leitch AG Hopkin JM Ellis DA The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis. Thorax 33 1978 711 713
7. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-44
8. Morris AH Kanner RE Crapo RO Clinical pulmonary function testing: a manual of uniform laboratory procedures. 2nd ed. 1984 Intermountain Thoracic Society Salt Lake City, Utah
9. Borg G. Psychophysical basis of perceived exertion. Med Sci Sports Exer 14 1982 377 381
10. McGavin CR Artvinli M Naoe H Dyspnea disability and distance walked: comparison of estimates of exercise performance in respiratory disease. BMJ 2 1978 241 243
11. Crapo RO Forster RE II. Carbon monoxide diffusing capacity. Clin Chest Med 10 1989 187 198
12. Ries AL. Measurement of lung volumes. Clin Chest Med 10 1989 177 186
13. Jones B Kenwood MG. Design and analysis of cross-over trials. 1989 Chapman and Hall; London 16 88
14. Karpel JP. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 99 1991 871 876
15. Guyatt GH Townsend M Nogradi S Acute response to bronchodilator. Arch Intern Med 148 1988 1949 1952
16. McGavin CR Gupta SP McHardy GJR. Twelve-minute walking test for assessing disability in chronic bronchitis. BMJ 1 1976 822 823
17. Gross NJ. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 139 1989 1188 1191
18. Tobin MJ Hughes JA Hutchison DCS. Effects of ipratropium bromide and fenoterol aerosols on exercise tolerance. Eur J Respir Dis 65 1984 441 446
19. Bernstein ML Despars JA Singh NP Reanalysis of the 12-minute walk in patients with chronic obstructive pulmonary disease. Chest 105 1994 163 167
20. Guyatt GH Townsend M Pugsley SO Bronchodilators in chronic air-flow limitation. Am Rev Respir Dis 135 1987 1069 1074